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320 LETTERS TO THE EDITORincreased proliferative capacity of cells expressing the exon 2
mutation. Our finding of bimodal FOXP3 expression in the carrier
differs from the only other published report of a carrier with an
exon 2 mutation (c.227delT) who expressed only one population
of CD41CD251CD127lo cells, all expressing WT FOXP3.7 Our
results are the first to confirm the natural ability of isoforms
lacking exon 2 to promote their own transcription, resulting in
expression of a functional isoform of FOXP3 that can support
Treg cell development.
In conclusion, we report a family with autoimmunity across 3
generations, including 2 affected male subjects. We have shown
that a milder IPEX phenotype was due to selective deletion of
FOXP3 exon 2 expression, resulting in loss of FOXP3fl but
retained expression of FOXP3D2. This report confirms that
FOXP3D2 can support Treg cell development in vivo andmitigate
at least some of the clinical features of complete FOXP3
deficiency, as observed in patients with classic IPEX syndrome.
These findings provide powerful patient-derived evidence for
the functional capabilities of the FOXP3D2 isoform. The variable
penetrance is important because it suggests that future patients
might be identified in populations with milder autoimmunity
not reaching the criteria for IPEX syndrome.
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https://doi.org/10.1016/j.jaci.2019.03.003Distribution of subsets of blood
monocytic cells throughout lifeTo the Editor:
Currently, it is well established that monocytes are a hetero-
geneous type of cell consisting of phenotypically and functionally
distinct subpopulations found to be numerically altered in blood
in patients with a wide variety of disease conditions, such as
infection, autoimmunity, respiratory and cardiovascular diseases,
and inflammatory disorders.1,2 Thus, 3 subpopulations of
circulating monocytic cells have been identified based on expres-
sion of the CD14 LPS receptor and the CD16 low-affinity Fc IgG
receptor: (1) CD14hiCD162 classical monocytes (cMos), (2)
CD14hiCD161 intermediate monocytes (iMos), and (3) CD142/lo
CD161 nonclassical monocytes (ncMos).3 Monocytes circulate
in blood for up to 3 days until recruited to virtually any human
tissue, where they differentiate into either tissue macrophages
ormyeloid dendritic cells.4 Then, tissuemacrophages canmigrate
from their tissue location through the lymph system5 before they
potentially die outside the circulation.6
Despite our knowledge of the biology of monocytes increasing
in recent years, normal reference ranges for the distinct monocyte
subsets in blood throughout life (eg, from cord blood [CB] and
newborns to elderly subjects) have never been systematically
defined. Moreover, the precise maturational and functional
relationship between the distinct populations of blood monocytes
and their tissue distribution profiles remains unknown.
To provide a frame of reference for future identification of
disease-associated altered profiles, we investigated the
distribution of distinct monocytic cell subsets in normal blood
versus secondary lymphoid tissues, such as bone marrow (BM),
lymph node, and spleen. Our aim was to shed light on changes in
the distribution of these monocytic cell subsets in blood and other
lymphoid tissues. For this purpose, a total of 188 EDTA-
anticoagulated blood samples were studied: 11 CB specimens
from full-term neonates and 177 blood samples from 164 healthy
subjects and 13 solid organ donors (102 male and 75 female
FIG 1. Distribution of different subsets of circulating monocytes in CB and peripheral blood samples from
healthy subjects through life. *P < .05 versus CB. #P < .05 versus subjects aged 30 or more to less than
50 years. 1P < .05 versus newborns. NB, Newborns.
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LETTERS TO THE EDITOR 321subjects) with a median age of 26 years (range, 4 days to 92 years)
distributed by age group, as shown in Table E1 in this article’s
Online Repository at www.jacionline.org. In addition, 9 BM
samples (6 from male and 3 from female subjects; median age,
49 years [age range, 21-83 years]) from 9 of the above referred
healthy donors, together with 13 lymph node and 13 spleen paired
samples (9 from male and 4 from female subjects; median age,
69 years [age range, 49-81 years]) collected in parallel with bloodspecimens from solid organ donors, were studied. All organ
donors were in brain death at the moment of tissue collection
(performed within the first hour after heart failure), with the
organs maintained as viable throughout the procedure.
Identification of different monocytic cell subsets was
performed by using highly sensitive 10-color flow cytometry.
The immunophenotypic criteria used for identification of
monocytic subpopulations, as well as the precise flow cytometry
FIG 2. Relative distribution of different subsets of monocytes in adult blood versus paired BM
and paired lymph node and spleen samples. A-E, *P < .05 versus blood. #P < .05 versus lymph nodes.
F-J, Multidimensional representations of distinct monocyte cell subsets in different tissues. P > .05 for
comparison of the 2 blood sample groups for all monocyte subsets.
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section in this article’s Online Repository at www.jacionline.org
(Tables E2 and E3). Five distinct subsets of monocytes were
systematically identified in every sample analyzed: (1) CD62L1
and (2) CD62L2 cMos; (3) iMos; and (4) SLAN2 and (5) SLAN1
ncMos. An additional population of FcεRI1CD14hiCD162
monocytes was also identified in a subset of samples stained
with anti-FcεRI (see Fig E1 in this article’s Online Repository
at www.jacionline.org).
Overall, our results show that the distribution of monocyte
subsets in blood varies substantially during life, particularly during
the first 6months of life,when allmonocyte subsets peaked (Fig 1);
however, although cMos reached their highest numbers in CB
samples, iMo and ncMo numbers peaked in newborns. These
homeostatic changes most likely reflect the high production rate
and release of recently generated CD62L1 classical BM
monocytes into blood7 and thereby the early-life requirement for
sufficient numbers of monocytes to fill the distinct tissues.
Afterward, the 3 major monocyte subsets decreased until the age
of 8 to 13 years, subsequently increased again at adolescence
(particularly CD62L1 cMos), and remained high in younger
adults, decreasing thereafter until the age of 30 to 50 years. From
50 years onward, all of the above monocyte subsets increased inblood, which might reflect an increased tissue turnover, apoptosis,
and/or ‘‘immunosenescence.’’8 Based on the overall pattern of dis-
tribution of monocytic subsets in blood, with sequential peaks for
cMos, iMos, and ncMos, particularly during the earliest periods of
life and after the age of 50 years, our results would support the
notion that iMos and ncMos might correspond to monocytic cell
subsets at more advanced stages of maturation than cMos, which
is also in accordancewith previous reports.9Whether suchmatura-
tion occurs in blood or outside the bloodstream is still a subject of
debate, although some reports support the notion that the
differentiation steps of cMos into iMos and ncMos more likely
occur outside the blood compartment rather than in the blood.6,9
To gain insight into the potential tissue relationship between
cMos and both iMos and ncMos, we further investigated the
distribution of the distinct subsets of monocytes in normal BM,
lymph node, and spleen samples. Our results showed that their
relative distribution varies substantially in BM, lymph node, and
spleen compared with that in blood (Fig 2). Thus, although
CD62L1 cMos were by far the most abundant subset of cMos in
blood and BM, they were outnumbered by CD62L2 cMos in
lymph node and spleen. Moreover, higher percentages of iMos
were found in lymph node and spleen versus both blood and BM,
in which this cell subset represented a minor monocytic
 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
J ALLERGY CLIN IMMUNOL
VOLUME 144, NUMBER 1
LETTERS TO THE EDITOR 323population. In contrast, ncMos were particularly represented in
blood and spleen samples, although they were found at very low
percentages inBMand lymphnode; interestingly, no (or very small
numbers of) SLAN1 ncMos were found in lymph node samples.
The predominance of CD62L2 cMos in lymph node and spleen
would most likely reflect the more mature nature of cMos in these
lymphoid tissues (vs BM and blood). Altogether, these findings
suggest that, consistent with in vivo 6,6-2H2 glucose monocyte
tracking studies,6,9 cMos might lose CD62L and differentiate
into iMos in lymphoid tissues. iMosmight then recirculate through
the lymph system2 and sequentially give rise to SLAN2 and
SLAN1 ncMos. Despite this, therewere no statistically significant
differences between the phenotypic profile of the different mono-
cytic subsets in blood versus lymph node and spleen (see Fig E2
in this article’s Online Repository at www.jacionline.org).
In summary, our results show that the number of circulating
blood monocytes and their subsets varies significantly throughout
life, which provides a frame of reference for further studies in
distinct disease conditions. The differential distribution of the
distinct monocyte subsets evaluated in different human tissues
might reflect distinct functional features and kinetics of mono-
cytic cell subsets throughout the body. Further studies are
required to confirm this hypothesis.
Daniela Damasceno, MSca
Cristina Teodosio, PhDb
Wouter B. L. van den Bossche, MDb,c
Martın Perez-Andres, PhDa
Sonia Arriba-Mendez, MD, PhDd
Luis Mu~noz-Bellvis, MD, PhDe
Alfonso Romero, MD, PhDf
Juan F. Blanco, MD, PhDg
Ana Remesal, MD, PhDd
Noemi Puig, MD, PhDh
Sergio Matarraz, PhDa
Jose Luis Vicente-Villardon, PhDi
Jacques J. M. van Dongen, MD, PhDb*
Julia Almeida, MD, PhDa*
Alberto Orfao, MD, PhDa*
on behalf of the TiMaScan Study Group
From athe Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service
(NUCLEUS) and Department of Medicine, University of Salamanca, and the Institute
of Biomedical Research of Salamanca (IBSAL) & CIBERONC, Salamanca, Spain;
bthe Department of Immunohematology and Blood Transfusion, Leiden University
Medical Center, Leiden, The Netherlands; cthe Department of Immunology, Erasmus
University Medical Center, Rotterdam, The Netherlands; dthe Pediatrics Service, Uni-
versity Hospital of Salamanca (Complejo Asistencial Universitario de Salamanca
[CAUSA]), Salamanca, Spain; eSurgery Service, University Hospital of Salamanca
(CAUSA), and Department of Surgery, University of Salamanca and IBSAL, Sala-
manca, Spain; fthe Primary Health Care Center ‘‘Miguel Armijo,’’ Primary Health
Care of Salamanca, Sanidad de Castilla y Leon (SACYL), Salamanca, Spain; gthe Or-
thopedics Service, University Hospital of Salamanca (CAUSA), and the Department
of Surgery, University of Salamanca and IBSAL, Salamanca, Spain; hthe Hematology
Service, University Hospital of Salamanca (CAUSA) and IBSAL, Salamanca, Spain;
and ithe Statistics Department, University of Salamanca, Salamanca, Spain. E-mail:
orfao@usal.es.
*These authors contributed equally to this work
This work has been partially supported by the following grants: RTICC RD12/0036/
0048-FEDER, Biomedical Research Networking Center Consortium–CIBER-
CIBERONC (CB16/12/00400-FEDER), PI13/01412-FEDER, PI16/00787-FEDER
from the Instituto de Salud Carlos III (ISCIII), Ministerio de Economıa y Competiti-
vidad, Madrid, Spain, and the European Research Council (ERC) under the European
Union’s Horizon 2020 Research and Innovation Programme (grant agreement ERC-
2015-AdG 695655 [TiMaScan]).
Disclosure of potential conflict of interest: J. J. M. van Dongen and A. Orfao report being
the inventors on patent PCT/NL2012/050132 (‘‘Methods and means for monitoring
disruption of tissue homeostasis in the total body’’); report being chairmen of the
EuroFlow scientific foundation, which receives royalties from licensed patents thatare collectively owned by the participants of the EuroFlow Foundation; and report
an Educational Services Agreement between BD Biosciences and their universities.
The rest of the authors declare that they have no relevant conflicts of interest.
REFERENCES
1. Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. The three human
monocyte subsets: implications for health and disease. Immunol Res 2012;53:41-57.
2. Lund H, Boysen P, Akesson CP, Lewandowska-Sabat AM, Storset AK. Transient
migration of large numbers of CD14(11) CD16(1) monocytes to the draining
lymph node after onset of inflammation. Front Immunol 2016;7:322.
3. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al.
Nomenclature of monocytes and dendritic cells in blood. Blood 2010;116:e74-80.
4. Boyette LB, Macedo C, Hadi K, Elinoff BD, Walters JT, Ramaswami B, et al.
Phenotype, function, and differentiation potential of human monocyte subsets.
PLoS One 2017;12:e0176460.
5. Faber TJ, Japink D, Leers MP, Sosef MN, von Meyenfeldt MF, Nap M. Activated
macrophages containing tumor marker in colon carcinoma: immunohistochemical
proof of a concept. Tumour Biol 2012;33:435-41.
6. Tak T, Drylewicz J, Conemans L, de Boer RJ, Koenderman L, Borghans JAM, et al.
Circulatory and maturation kinetics of human monocyte subsets in vivo. Blood
2017;130:1474-7.
7. Prabhu SB, Rathore DK, Nair D, Chaudhary A, Raza S, Kanodia P, et al.
Comparison of human neonatal and adult blood leukocyte subset composition
phenotypes. PLoS One 2016;11:e0162242.
8. Simon AK, Hollander GA, McMichael A. Evolution of the immune
system in humans from infancy to old age. Proc Biol Sci 2015;282:
20143085.
9. Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, et al. The fate
and lifespan of human monocyte subsets in steady state and systemic inflammation.
J Exp Med 2017;214:1913-23.
Available online March 16, 2019.
https://doi.org/10.1016/j.jaci.2019.02.030Autonomous regulation of IgE-
mediated mast cell degranulation and
immediate hypersensitivity reaction
by an inhibitory receptor CD300aTo the Editor:
Although phosphatidylserine (PS) confined to the inner leaflet
of plasma membrane is exposed on the cell surface when cells
undergo apoptosis, viable cells, including mast cells (MCs), also
externalize PS in certain cellular states.1,2,E1-E3 However, the
pathophysiological significance of PS exposure on viable cells
remains elusive. To address the role of PS externalization on
the cell surface of viable MCs, we monitored PS surface exposure
on bone marrow–derived cultured MCs (BMMCs) by confocal
microscopy after stimulation with trinitrophenyl (TNP)-specific
IgE and TNP-ovalbumin (OVA) in the presence of PSVue 643,
a fluorescent dye with rapid binding capacity for PS. The dye
began to accumulate on the cell surface of live BMMCs within
600 seconds after FcεRI stimulation, whereas the nonstimulated
BMMCs remained negative for the staining (Fig 1, A; see Video
E1 in this article’s Online Repository at www.jacionline.org),
indicating that PS is externalized within 10 minutes after
activation.
MCs abundantly express CD300a, an inhibitory immunore-
ceptor for PS.3-5 By imaging flow cytometry analyses, we found
that both PS and CD300a showed a polarization andND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
METHODS
Subjects and samples
A total of 188 EDTA-anticoagulated blood samples were studied. Eleven
CB specimens from full-term neonates of healthy mothers and 177 blood
samples from 164 healthy subjects and 13 solid organ donors (102male and 75
female subjects; median age, 26 years [age range, 4 days to 92 years]) were
acquired with the following age distribution: newborns (median, 4.5 days
[range, 4-10 days]), 4 cases; children 1 ormore to less than 6months of age, 14
subjects; children 6 ormore to less than 12months of age, 10 subjects; children
1 year or more to less than 2 years, 13 subjects; children 2 or more years to less
than 5 years, 18 subjects; children 5 or more years to less than 8 years, 18
subjects; children 8 or more years to less than 13 years, 17 subjects; children
13 or more years to less than 16 years, 6 subjects; children 16 or more years to
less than 20 years, 5 subjects; adults 20 or more years to less than 30 years, 13
subjects; adults 30 or more years to less than 50 years, 15 subjects; adults 50 or
more years to less than 60 years, 13 subjects; adults 60 or more years to less
than 70 years, 10 subjects; adults 70 or more years to less than 80 years, 9
subjects; and adults 80 or more years, 12 subjects (Table E1). CB, childhood,
and adult samples were collected at the Erasmus University Medical Center;
the University Hospital of Salamanca, Salamanca; and the corresponding pri-
mary health care centers of Salamanca, respectively.
In addition, 9 normal BM samples (6 frommale and 3 from female subjects;
median age, 49 years [age range, 21-83 years]) collected in parallel to blood
samples from 9 healthy donors (undergoing orthopedic surgery) and 13 lymph
node plus 13 spleen paired samples (9 from male and 4 from female subjects;
median age, 69 years [age range, 49-81 years]) collected from solid organ
donors (in addition to paired blood samples) at the Surgery Service of the
University Hospital of Salamanca were studied in parallel. All organ donors
were in brain death at the moment of tissue collection (performed within the
first hour after heart failure), with the organs maintained as viable throughout
the procedure, according to the standard transplantation protocol.
All study subjects had no medical history of either immunologic or
oncohematologic disorders. All participants, except for the anonymized solid
organ donors, were enrolled in the study after informed consent was provided
by each subject, their corresponding legal representative, or both. The study
was approved by the Ethics Committee of the University Hospital of




All samples (fresh whole CB, blood, BM, lymph node, and spleen
specimens) were stained and processed within less than 1 to 24 hours after
collection. For CB, blood, and BM samples, the EuroFlow bulk-lyse standard
operating procedureE1 was used to lyse nonnucleated red cells before staining.
Lymph node and spleen samples were mechanically dissociated into single-
cell suspensions before staining.E2 Afterward, 53 106 leukocytes per sample
aliquot were stained with a single 10-color combination of the following mAb
reagents (mAb [clone]–fluorochrome; see Tables E2 and E3): CD45 (HI30)–
Pacific Orange, CD62L (DREG-56)–Brilliant Violet 650, CD16 (3G8)–
Brilliant Violet 786, CD36 (CLB-IVC7)–fluorescein isothiocyanate, CD14
(M4P9)–peridinin chlorophyll protein-cyanine 5.5 (PerCP-Cy5.5), anti-
SLAN (DD-1)–phycoerythrin (PE), CD33 (WM53)–PE-CF594, anti–HLA-
DR (G46-6)–PE–cyanine 7, CD64 (10.1)– allophycocyanin, and CD300e
(UP-H2)–allophycocyanin–cyanine 750. In a subset of 15 specimens (3 blood,
6 BM, 3 lymph node, and 3 spleen samples), anti-FcεRI (clone AER-37) was
also added in a PE-conjugate format in addition to the anti–SLAN-PE reagent
(Tables E2 and E3) because the monocyte subsets expressing each of these 2
markers were mutually exclusive (data not shown). In BM samples additional
markers were also included to further identify uncommittedmonocytic precur-
sors: CD34 (P67.6)–PerCP-Cy5.5 and CD117 (YB5.B8)–PE-CF594 (Tables
E2 and E3). Reagents were purchased from BD (San Jose, Calif), except
CD45 (Thermo Fisher Scientifics, Waltham, Mass), CD36 (Cytognos S.L.,
Salamanca, Spain), anti-SLAN (Milteny Biotec, Cologne, Germany), and
both CD300e and anti-FcεRI (IMMUNOSTEP, Salamanca, Spain). Sample
acquisition was performed immediately after immunostaining with LSR For-
tessa X-20 flow cytometers (BD) using FACSDiva software (BD). For instru-
ment setup, calibration, and monitoring, the EuroFlow instrument setup and
compensation protocol (www.EuroFlow.org) for 12-color measurements
was used. For data analysis, the Infinicyt software (Cytognos S.L) was used.
For each blood sample, relative and absolute (double-platform) cell counts
were calculated and recorded for both the whole monocyte population and
each monocytic subset. In BM, lymph node, and spleen samples only relative
cell counts were derived. The gating strategy used for identification of each
cell subset is shown in Fig E1.
Statistical analyses
For continuous variables, medians, means, and SDs, as well as ranges and
10th, 25th, 75th, and 90th percentiles, were calculated; for categorical
variables, frequencies were used. The statistical significance of differences
observed between 2 or more groups was assessed by using nonparametric
Mann–Whitney U and Kruskal–Wallis tests for independent variables,
respectively. For comparisons between 2 or more groups of paired samples,
nonparametric Friedman and Wilcoxon tests were used, respectively.
Spearman rank correlation (R software package, www.R-project.org) was
used to explore the degree of association between 2 continuous variables.
For all statistical analyses (but Spearman rank correlation), the SPSS soft-
ware program (IBM-SPSS Statistics version 23; IBM, Armonk, NY) was
used. P values of .05 or less were considered to be associated with statistical
significance.
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FIG E1. Identification of different subsets of circulating monocytes in representative peripheral blood and
BM samples from a healthy donor.
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FIG E2. Comparison between the phenotypic profile of the different subsets of monocytic cells in BM,
lymph node, and spleen versus blood.
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TABLE E1. Age and sex distribution of 177 subjects whose blood
samples were analyzed for the distribution of circulating mono-
cyte/macrophage cell subsets
Age group Male subjects Female subjects Total
NB 1 3 4
>_1 to <6 mo 13 1 14
>_6 to <12 mo 10 0 10
>_1 to <2 y 8 5 13
>_2 to <5 y 10 8 18
>_5 to <8 y 7 11 18
>_8 to <13 y 11 6 17
>_13 to <16 y 4 2 6
>_16 to <20 y 2 3 5
>_20 to <30 y 5 8 13
>_30 to <50 y 8 7 15
>_50 to <60 y 5 8 13
>_60 to <70 y 6 4 10
>_70 to <80 y 7 2 9
>_80 y 5 7 12
Total 102 75 177
NB, Newborns.
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TABLE E2. Ten-color combinations of fluorochrome-conjugated mAbs used for identification of monocytic cells and their subsets in the
different samples studied: Panel used for immunophenotyping CB, peripheral blood, lymph node, and spleen samples
PacO BV650 BV785 FITC PerCP-Cy5.5 PE PE-CF594 PE-Cy7 APC APC-C750
Panel 1 CD45 CD62L CD16 CD36 CD14 Anti-SLAN 1 anti-FcεRI* CD33 HLADR CD64 CD300e
Reagent source Thermo Fisher BD BD Cytognos BD Miltenyi Biotec 1 IMMUNOSTEP BD BD BD IMMUNOSTEP
APC, Allophycocyanin; APC-C750, allophycocyanin–cyanine 750; BV, Brilliant Violet; FITC, fluorescein isothiocyanate; PacO, Pacific Orange; PE-Cy7, phycoerythrin–cyanine 7;
PerCP-Cy5.5, peridinin chlorophyll protein–cyanine 5.5.
*Included in a subset of 3 PB samples, 1 lymph node sample, and 1 spleen sample.
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TABLE E3. Ten-color combinations of fluorochrome-conjugated mAbs used for the identification of monocytic cells and their subsets in
the different samples studied: Panel used for immunophenotyping BM samples
PacO BV650 BV785 FITC PerCP-Cy5.5 PE PE-CF594 PE-Cy7 APC APC-C750
Panel 2 CD45 CD62L CD16 CD36 CD14 1 CD34 Anti-SLAN 1 anti-FcεRI* CD117 HLA-DR CD64 CD300e
Reagent
source
Thermo Fisher BD BD Cytognos BD Miltenyi Biotec 1
IMMUNOSTEP
BD BD BD IMMUNOSTEP
APC, Allophycocyanin; APC-C750, allophycocyanin–cyanine 750; BV, Brilliant Violet; FITC, fluorescein isothiocyanate; PacO, Pacific Orange; PE-Cy7, phycoerythrin–cyanine 7;
PerCP-Cy5.5, peridinin chlorophyll protein–cyanine 5.5.
*Included in a subset of 3 PB samples, 1 lymph node sample, and 1 spleen sample.
Included in a subset of 7 BM samples.
J ALLERGY CLIN IMMUNOL
VOLUME 144, NUMBER 1
LETTERS TO THE EDITOR 323.e6
